All results
8 results for ovarian cancer
-
Bleomycin, Carboplatin, Etoposide, or Cisplatin in Pediatric and Adult Patients With Germ Cell Tumor
This partially randomized phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and…
- Ages
- N/A - N/A
- Sexes
- All
-
Comparing Two Surgical Procedures in Individuals with Ovarian Cancer+BRCA1 Mutations(SOROCk)
This clinical trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian…
- Ages
- 35 Years - 50 Years
- Sexes
- Female
-
HIIT following breast cancer chemotherapy
Chemotherapy is an effective breast cancer treatment, which helped to increase the 5-year survival rate to approximately 95%. However, breast cancer survivors…
- Ages
- 18 Years - 85 Years
- Sexes
- Female
-
Indoor Rowing as Therapy for Cardiovascular Rehabilitation in Breast Cancer Survivors
There are more than 3.8 million breast cancer survivors in the United States and cancer survivors have a higher risk of cardiovascular disease (CVD) due to…
- Ages
- 40 Years - 80 Years
- Sexes
- Female
-
NRG-BR009: Testing the addition of chemo to SOC in breast cancer patients at high risk of recurrence
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to…
- Ages
- 18 Years - 60 Years
- Sexes
- Female
-
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Testing the Combination of ZEN-3694 and Talazoparib in Ps w/ Advanced Solid Tumors; ComBET
This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely…
- Ages
- 18 Years - N/A
- Sexes
- All